C4 glomerulopathy pathophysiology

Jump to navigation Jump to search

C4 glomerulopathy Microchapters

Complement Mediated Glomerular Disorders Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating C4 glomerulopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

C4 glomerulopathy pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of C4 glomerulopathy pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on C4 glomerulopathy pathophysiology

CDC on C4 glomerulopathy pathophysiology

C4 glomerulopathy pathophysiology in the news

Blogs on C4 glomerulopathy pathophysiology

Directions to Hospitals Treating C4 glomerulopathy

Risk calculators and risk factors for C4 glomerulopathy pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

It is thought that C4 glomerulopathy is the result of the activation of immune complex glomerulonephritis or lectin pathway of the complement.

Pathophysiology

  • The generation of the classical pathway of complement occurs by the immune complex.
  • Immune complex glomerulonephritis, such as lupus, frequently activates the classical pathway by binding C1q to the antibody-containing immune complexes, which can result in glomerular deposition of immunoglobulins, C3, C1q, and C4d.
  • C4 activation can also ensue by the lectin pathway of complement.
  • In the lectin pathway, mannose-binding lectins bind to mannose located on the carbohydrates structure or microbial membranes, which activate C4 (and therefore bypass C1q), resulting in the formation of the classical pathway C3 convertase.
  • Glomerular C4d, is a split creation of C4, is suggestive of C4 activation as a result of activation of either the lectin pathway of the classical complement pathway.
  • In C4 glomerulopathy, bright streak for C4d indicates mesangial/capillary wall deposits. C4d deposits are present in a few cases of IgA nephropathy and post-streptococcal glomerulonephritis[1][2][3][4][5].

References

  1. Sethi S, Nasr SH, De Vriese AS, Fervenza FC (2015). "C4d as a Diagnostic Tool in Proliferative GN". J Am Soc Nephrol. 26 (11): 2852–9. doi:10.1681/ASN.2014040406. PMC 4625660. PMID 25991041.
  2. Larsen CP, Messias NC, Walker PD, Fidler ME, Cornell LD, Hernandez LH; et al. (2015). "Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits". Kidney Int. 88 (4): 867–73. doi:10.1038/ki.2015.195. PMC 4687465. PMID 26154922.
  3. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB; et al. (2004). "The classification of glomerulonephritis in systemic lupus erythematosus revisited". J Am Soc Nephrol. 15 (2): 241–50. doi:10.1097/01.asn.0000108969.21691.5d. PMID 14747370.
  4. Batal I, Liang K, Bastacky S, Kiss LP, McHale T, Wilson NL; et al. (2012). "Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study". Lupus. 21 (1): 13–26. doi:10.1177/0961203311422093. PMID 21959138.
  5. Espinosa M, Ortega R, Sánchez M, Segarra A, Salcedo MT, González F; et al. (2014). "Association of C4d deposition with clinical outcomes in IgA nephropathy". Clin J Am Soc Nephrol. 9 (5): 897–904. doi:10.2215/CJN.09710913. PMC 4011455. PMID 24578331.

Template:WHTemplate:WS